International Journal of Infectious Diseases
Volume 13, Issue 4 , Pages 483-487 , July 2009

Pharmacodynamic target attainment potential of azithromycin, clarithromycin, and telithromycin in serum and epithelial lining fluid of community-acquired pneumonia patients with penicillin-susceptible, intermediate, and resistant Streptococcus pneumoniae

  • Ayman M. Noreddin

      Affiliations

    • College of Pharmacy, University of Minnesota, 1110 Kirby Dr., Duluth, MN 55812, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 218 726 6028; fax: +1 218 726 6500.
    • ,
  • Walid F. El-Khatib

      Affiliations

    • College of Pharmacy, University of Minnesota, 1110 Kirby Dr., Duluth, MN 55812, USA
    • Faculty of Pharmacy, Ain-Shams University, Cairo, Egypt
    • ,
  • Jason Aolie

      Affiliations

    • College of Pharmacy, University of Minnesota, 1110 Kirby Dr., Duluth, MN 55812, USA
    • ,
  • Ahmed H. Salem

      Affiliations

    • College of Pharmacy, University of Minnesota, 1110 Kirby Dr., Duluth, MN 55812, USA
    • Faculty of Pharmacy, Ain-Shams University, Cairo, Egypt
    • ,
  • George G. Zhanel

      Affiliations

    • Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada

Received 25 May 2008 ,Revised 31 July 2008 ,Accepted 15 August 2008.

References 

  1. Mandell LA. Epidemiology and etiology of community-acquired pneumonia. Infect Dis Clin North Am. 2004;18:761–776
  2. Sinus and Allergy Health Partnership. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg. 2004;130(1 Suppl):S1–45Ann Intern Med 1991;114:731–4
  3. Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weissfeld LA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA. 1996;275:134–141
  4. Tomasz A. New faces of an old pathogen: emergence and spread of multidrug-resistant Streptococcus pneumoniae. Am J Med. 1999;107:S55–S62
  5. Doern GV, Brueggemann A, Holley HP, Rauch AM. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother. 1996;40:1208–1213
  6. Jorgensen JH, Doern GV, Maher LA, Howell AW, Redding JS. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother. 1990;34:2075–2080
  7. Doern GV, Pfaller MA, Kugler K, Freeman J, Jones RN. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program. Clin Infect Dis. 1998;27:764–770
  8. Thornsberry C, Brown SD, Yee C, Bouchillon SK, Marler JK, Rich T. Increasing penicillin resistance in Streptococcus pneumoniae in the U. S. Infect Med. 1993;93(Suppl):15–24
  9. Doern GV, Heilmann KP, Huynh HK, Rhomberg PR, Coffman SL, Brueggemann AB. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999–2000, including a comparison of resistance rates since 1994–1995. Antimicrob Agents Chemother. 2001;45:1721–1729
  10. Pankuch GA, Visalli MA, Jacobs MR, Appelbaum PC. Susceptibilities of penicillin- and erythromycin-susceptible and resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents. Antimicrob Agents Chemother. 1998;42:624–630
  11. Drusano GL, Craig WA. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. J Chemother. 1997;9(Suppl 3):38–44
  12. Tessier PR, Mattoes HM, Dandekar PK, Nightingale CH, Nicolau DP. Pharmacodynamic profile of telithromycin against macrolide- and fluoroquinolone-resistant Streptococcus pneumoniae in a neutropenic mouse thigh model. Antimicrob Agents Chemother. 2005;49:188–194
  13. Craig WA, Andes DR. Differences in the in vivo pharmacodynamics of telithromycin and azithromycin against Streptococcus pneumoniae [abstract 2141]. In: Programs and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto: American Society for Microbiology; 2000, p. 32.
  14. Carbon C. Pharmacodynamics of macrolides, azalides, and streptogramins: effect on extracellular pathogens. Clin Infect Dis. 1998;27:28–32
  15. Novelli A, Fallani S, Cassetta MI, Arrigucci S, Mazzei T. In vivo pharmacodynamic evaluation of clarithromycin in comparison to erythromycin. J Chemother. 2002;14:584–590
  16. Periti P, Mazzei T. Clarithromycin: pharmacokinetic and pharmacodynamic interrelationships and dosage regimen. J Chemother. 1999;11:11–27
  17. Tessier PR, Kim MK, Zhou W, Xuan D, Li C, Ye M, et al. Pharmacodynamic assessment of clarithromycin in a murine model of pneumococcal pneumoniae. Antimicrob Agents Chemother. 2002;46:1425–1434
  18. Sinus and Allergy Health Partnership. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Executive Summary. Otolaryngol Head Neck Surg. 2004;130(1 Suppl):1–45
  19. Lodise TP, Preston S, Bhargava V, Bryskier A, Nusrat R, Chapel S, et al. Pharmacodynamics of an 800mg dose of telithromycin in patients with community-acquired pneumonia caused by extracellular pathogens. Diagn Microbiol Infect Dis. 2005;52:45–52
  20. Zhanel GG, Dueck M, Hoban DJ, Vercaigne LM, Embil JM, Gin AS, et al. Review of macrolides and ketolides: focus on respiratory tract infections. Drugs. 2001;61:443–498
  21. Zhanel GG, Palatnick L, Nichol K, Bellyou T, Low DE, Hoban DJ. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother. 2003;47:1867–1874
  22. Zhanel GG, Karlowsky JA, Palatnick L, Vercaigne L, Low DE The Canadian Respiratory Infection Study Group. Prevalence of antimicrobial resistance in respiratory tract isolates of Streptococcus pneumoniae: results of a Canadian national surveillance study. Antimicrob Agents Chemother. 1999;43:2504–2509
  23. Hammersley JM, Handscomb DC. Monte Carlo simulation. In: Monte Carlo methods. London: Methuen and Co. Ltd; 1964;
  24. Thompson KM, Burmaster DE, Crouch EA. Monte Carlo techniques for quantitative uncertainty analysis in public health risk assessments. Risk Anal. 1992;12:53–63
  25. Burmaster DE, Anderson PD. Principles of good practice for the use of Monte Carlo techniques in human health and ecological risk assessments. Risk Anal. 1994;14:477–481
  26. Zhanel GG, DeCorby M, Noreddin A, Mendoza C, Cumming A, Nichol K, et al. Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations. J Antimicrob Chemother. 2003;52:83–88
  27. Zhanel GG, Johanson C, Hisanaga T, Mendoza C, Laing N, Noreddin A, et al. Pharmacodynamic activity of telithromycin against macrolide-susceptible and macrolide-resistant Streptococcus pneumoniae simulating clinically achievable free serum and epithelial lining fluid concentrations. J Antimicrob Chemother. 2004;54:1072–1077
  28. Vanderkooi OG, Low DE, Green K, Powis JE, McGeer A. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis. 2005;40:1288–1297

☆ This study was presented at the International Society of Chemotherapy Third International Conference on Community Acquired Pneumonia (ISC-CAP), April 14–16, 2007, Montreal, Quebec, Canada.

PII: S1201-9712(08)01540-3

doi: 10.1016/j.ijid.2008.08.016

International Journal of Infectious Diseases
Volume 13, Issue 4 , Pages 483-487 , July 2009

Article Tools

* Image Usage & Resolution